Workflow
Volition Introduces Nu.Q® Cancer Blood Test in New Industry Primer for Lung Cancer
VNRXVolition(VNRX) Prnewswire·2025-03-20 12:30

Core Viewpoint - VolitionRx Limited aims to transform the lung cancer diagnosis and monitoring landscape with its Nu.Q® Cancer Test, targeting the 4billionlungcancermarket[1][4].CompanyOverview−VolitionRxLimitedisamulti−nationalepigeneticscompanyfocusedonadvancingearlydetectionandmonitoringofdiseases,includingcancer[6][7].−Thecompanyisdevelopingcost−effectivebloodteststhatcanbeadministeredeasily,utilizingsmallbloodsamples[1][7].ProductDevelopment−TheNu.Q®Cancerassaysaredesignedtoimproveearlydetectionandmonitoringoflungcancer,potentiallyenhancingpatientoutcomes[1][3].−Aretrospectivestudyinvolving1,050patientswithNon−SmallCellLungCancerissettobepublished,supportingtheefficacyofNu.Q®Cancer[4].MarketOpportunity−Thetotalannualaccessiblemarketforlungcancerscreening,prognostication,andminimalresidualdiseaseidentificationisestimatedatapproximately4 billion lung cancer market [1][4]. Company Overview - VolitionRx Limited is a multi-national epigenetics company focused on advancing early detection and monitoring of diseases, including cancer [6][7]. - The company is developing cost-effective blood tests that can be administered easily, utilizing small blood samples [1][7]. Product Development - The Nu.Q® Cancer assays are designed to improve early detection and monitoring of lung cancer, potentially enhancing patient outcomes [1][3]. - A retrospective study involving 1,050 patients with Non-Small Cell Lung Cancer is set to be published, supporting the efficacy of Nu.Q® Cancer [4]. Market Opportunity - The total annual accessible market for lung cancer screening, prognostication, and minimal residual disease identification is estimated at approximately 4 billion [4]. - VolitionRx is in discussions with large diagnostics and liquid biopsy companies to establish multiple licensing agreements this year [4]. Commercial Strategy - The company's nucleosome assays can be utilized on existing automated chemiluminescence platforms, eliminating the need for new hardware [5]. - VolitionRx aims to make Nu.Q® Cancer testing widely accessible through licensing and partnership arrangements [5].